Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas

Oncology Reports

Volumn 16, Issue 5, 2006, Pages 957-963

  Ohta, Takashi ^a   Watanabe, Takao ^a   Katayama, Yoichi ^a   Yoshino, Atsuo ^a   Yachi, Kazunari ^a   Ogino, Akiyoshi ^a   Komine, Chiaki ^a   Fukushima, Takao ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic astrocytoma; Cell cycle regulatory gene; Glioblastoma multiforme; Prognosis; Promoter methylation

Indexed keywords

CELL CYCLE PROTEIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGED; ARTICLE; ASTROCYTOMA; DNA METHYLATION; FEMALE; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; CELL CYCLE PROTEINS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 33847242813     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.5.957     Document Type: Article

References (47)

1. Klihues P and Ohgaki H: Primary and secondary glioblastomas: from the concept to clinical diagnosis. Neurooncology 1: 44-51, 1999.
2. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004. (Pubitemid 39330996)
3. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 25: 1-7, 2005.
4. Hannon GJ and Beach D: p15INK4b is a potential effecter of TGF-beta-induced cell cycle arrest. Nature 371: 257-261, 1994.
5. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
6. Dulic V, Kaufmann WK, Wilson SJ, et al: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994. (Pubitemid 24106382)
7. Quelle DE, Zindy F, Ashmun RA and Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995. (Pubitemid 26006540)
8. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998. (Pubitemid 28326106)
9. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998.
10. Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734, 1998. (Pubitemid 28155312)
11. Esteller M, Corn PC, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001. (Pubitemid 32695003)
12. Xu XL, Yu J, Zhang HY, Sun MH, et al: Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 23: 3441-3454, 2004.
13. Kawamata N, Inagaki N, Mizumura S, Sugimoto K, Sakajiri S, Ohyanagi-Hara M and Oshima K: Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 74: 424-429, 2005. (Pubitemid 40545568)
14. Wong IHV, Ng MHL, Huang DP and Lee JCK: Aberrant p15 promoter methylation in adult and children acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95: 1942-1949, 2000. (Pubitemid 30151630)
15. Roman-Gomez J, Castillejo JA, Jimenez A, et al: 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291-2296, 2002. (Pubitemid 34525411)
16. Gonzales-Gomes P, Bello MJ, Arjona D, et al : Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 22: 601-608, 2003.
17. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001.
18. Yu J, Zhang H, Gu J, et al: Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. Biomed Chromatogr Cancer 65: 4884-4890, 2004.
19. INK4a genes in oligodendrogliomas. Acta Neuropathol 101: 185-189, 2001.
20. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P and Ohgaki H: Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60: 1181-1189, 2001. (Pubitemid 33117098)
21. Watanabe T, Huang H, Nakamura M, Wischusen J, Weller M, Kleihues P and Ohgaki H: Methylation of the p73 gene in gliomas. Acta Neuropathol 104: 357-362, 2002. (Pubitemid 36075399)
22. ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9: 4884-4890, 2003.
23. Kleihues P and Cavenee WK: Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon, 2000.
24. Watanabe T, Katayama Y, Yoshino A, Fukaya C and Yamamoto T: Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 72: 57-62, 2005. (Pubitemid 41149178)
25. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
26. INK4A/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64: 398-403, 2005.
27. 6- Methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113: 581-587, 2005.
28. Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997. (Pubitemid 27357971)
29. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB and Herman JG: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitts's lymphoma is associated with 5'CpG island methylation. Cancer Res 59: 3352-3356, 1999. (Pubitemid 29334490)
30. Dong S, Pang JCS, Hu J, Zhou LF and Ng HK: Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 98: 370-375, 2002. (Pubitemid 34188680)
31. Kang MJ, Park BJ, Byun DS, Park JI, Kim HJ, Park JH and Chi SG: Loss of imprinting and elevated expression of wildtype p73 in human gastric adenocarcinoma. Clin Cancer Res 6: 1767-1771, 2000.
32. Tannapfel A, Wasner M, Krause K, et al: Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 91: 1154-1158, 1999. (Pubitemid 29330554)
33. Chen CL, Ip SM, Cheng D, Wong LC and Ngan HYS: p73 gene expression in ovarian cancer tissues and cell lines. Clin Cancer Res 6: 3910-3915, 2000.
34. Sun XF: p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 8: 165-170, 2002.
35. Melino G, De Laurenzi V and Vousden KH: p73: friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615, 2002. (Pubitemid 37328927)
36. Jost CA, Marin MC and Kaelin WG Jr: p73 is a simian p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997. (Pubitemid 27400602)
37. Ozaki T and Nakagawara A: p73, a sophisticated p53 family member in the cancer world. Cancer Sci 96: 729-737, 2005. (Pubitemid 43019823)
38. Liu SS, Leung RCY, Chan KYK, et al: p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res 10: 3309-3316, 2004. (Pubitemid 38685435)
39. Casciano I, Mazzocco K, Boin L, et al: Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251, 2002. (Pubitemid 34223868)
40. Uramoto H, Sugio K, Oyama T, et al: Expression of ΔNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004. (Pubitemid 39383040)
41. Loiseau H, Arsaut J and Demotes-Mainard J: p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett 263: 173-176, 1999. (Pubitemid 29158956)
42. Kamiya M and Nakazato Y: The expression of p73, p21 and MDM2 proteins in gliomas. J Neurooncol 59: 143-149, 2002. (Pubitemid 35021562)
43. Ugur H, Sayan AE, Ozdamar SO, Kanpolat Y and Ozturk M: Expression of TAP73 and DeltaNP73 in malignant gliomas. Oncol Rep 11: 1337-1341, 2004.
44. Kip1is correlated with survival of patients with astrocytoma. Clin Cancer Res 5: 551-557, 1999.
45. Kirla RM, Haapasalo HK, Kalimo H and Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97: 644-648, 2001.
46. KIP1) on malignant glioma cells. Br J Cancer 88: 1277-1280, 2003.
47. Loda M, Cukor B, Tam SW, et al : Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat Med 3: 231-234, 1997. (Pubitemid 27064711)